Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

IL1RAP potentiates multiple oncogenic signaling pathways in AML.

Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U.

J Exp Med. 2018 Jun 4;215(6):1709-1727. doi: 10.1084/jem.20180147. Epub 2018 May 17.

2.

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, Högberg C, Rissler M, Wunderlich M, Juliusson G, Richter J, Sjöström K, Bhatia R, Mulloy JC, Järås M, Fioretos T.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10786-91. doi: 10.1073/pnas.1422749112. Epub 2015 Aug 10.

3.

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.

Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U.

Blood. 2012 Aug 9;120(6):1290-8. doi: 10.1182/blood-2012-01-404699. Epub 2012 Jun 21.

4.

Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.

Askmyr M, Ågerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, Juliusson G, Richter J, Järås M, Fioretos T.

Blood. 2013 May 2;121(18):3709-13. doi: 10.1182/blood-2012-09-458935. Epub 2013 Mar 11.

5.

Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.

Drexler HG.

Leukemia. 1996 Apr;10(4):588-99. Review.

PMID:
8618433
6.

IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients.

Zhao K, Yin LL, Zhao DM, Pan B, Chen W, Cao J, Cheng H, Li ZY, Li DP, Sang W, Zeng LY, Xu KL.

Int J Clin Exp Med. 2014 Dec 15;7(12):4787-98. eCollection 2014.

7.

Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.

Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M.

Cytometry A. 2015 Apr;87(4):346-56. doi: 10.1002/cyto.a.22628. Epub 2015 Jan 16.

8.

IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.

Ågerstam H, Hansen N, von Palffy S, Sandén C, Reckzeh K, Karlsson C, Lilljebjörn H, Landberg N, Askmyr M, Högberg C, Rissler M, Porkka K, Wadenvik H, Mustjoki S, Richter J, Järås M, Fioretos T.

Blood. 2016 Dec 8;128(23):2683-2693. Epub 2016 Sep 12.

9.

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.

Järås M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, Lassen C, Olofsson T, Bjerrum OW, Richter J, Fioretos T.

Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16280-5. doi: 10.1073/pnas.1004408107. Epub 2010 Aug 30.

10.

Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells.

Dehmel U, Zaborski M, Meierhoff G, Rosnet O, Birnbaum D, Ludwig WD, Quentmeier H, Drexler HG.

Leukemia. 1996 Feb;10(2):261-70.

PMID:
8637235
11.

Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.

Cook AM, Li L, Ho Y, Lin A, Li L, Stein A, Forman S, Perrotti D, Jove R, Bhatia R.

Blood. 2014 May 1;123(18):2826-37. doi: 10.1182/blood-2013-05-505735. Epub 2014 Mar 25.

12.

CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.

Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, Spiekermann K.

Clin Cancer Res. 2009 Apr 1;15(7):2238-47. doi: 10.1158/1078-0432.CCR-08-1325. Epub 2009 Mar 10.

13.

Role of misfolded N-CoR mediated transcriptional deregulation of Flt3 in acute monocytic leukemia (AML)-M5 subtype.

Nin DS, Kok WK, Li F, Takahashi S, Chng WJ, Khan M.

PLoS One. 2012;7(4):e34501. doi: 10.1371/journal.pone.0034501. Epub 2012 Apr 13.

14.

The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.

Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W.

Blood. 2003 Feb 15;101(4):1494-504. Epub 2002 Oct 24.

15.

Misfolded N-CoR is Linked to the Ectopic Reactivation of CD34/Flt3-Based Stem-Cell Phenotype in Promyelocytic and Monocytic Acute Myeloid Leukemia.

Nin DS, Li F, Visvanathan S, Khan M.

Front Oncol. 2015 Oct 7;5:210. doi: 10.3389/fonc.2015.00210. eCollection 2015.

16.

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.

Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM.

Mol Cancer Ther. 2011 Jun;10(6):1028-35. doi: 10.1158/1535-7163.MCT-10-1044. Epub 2011 Apr 11.

17.

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.

Pillinger G, Abdul-Aziz A, Zaitseva L, Lawes M, MacEwan DJ, Bowles KM, Rushworth SA.

Sci Rep. 2015 Aug 21;5:12949. doi: 10.1038/srep12949.

18.

Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.

Hassan HT, Zander A.

Acta Haematol. 1996;95(3-4):257-62. Review.

PMID:
8677752
19.

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.

Park IK, Mishra A, Chandler J, Whitman SP, Marcucci G, Caligiuri MA.

Blood. 2013 Mar 14;121(11):2064-73. doi: 10.1182/blood-2012-07-444018. Epub 2013 Jan 15.

20.

microRNA-4331 Promotes Transmissible Gastroenteritis Virus (TGEV)-induced Mitochondrial Damage Via Targeting RB1, Upregulating Interleukin-1 Receptor Accessory Protein (IL1RAP), and Activating p38 MAPK Pathway In Vitro.

Zhao X, Bai X, Guan L, Li J, Song X, Ma X, Guo J, Zhang Z, Du Q, Huang Y, Tong D.

Mol Cell Proteomics. 2018 Feb;17(2):190-204. doi: 10.1074/mcp.RA117.000432. Epub 2017 Dec 7.

Supplemental Content

Support Center